Current, new and future treatments in dyslipidaemia and atherosclerosis

Drugs

Volumn 60, Issue 1, 2000, Pages 55-93

  Chong, P H ^a   Bachenheimer, B S ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b MIDWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BEZAFIBRATE; BILE ACID; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CLOFIBRATE; ESTROGEN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; NICOTINIC ACID; PROBUCOL; PROGESTERONE; RALOXIFENE; RECOMBINANT PROTEIN; RESIN; SIMVASTATIN; STATIN; TAMOXIFEN; THYROMIMETIC AGENT; TRIACYLGLYCEROL; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; DRUG ANTAGONISM; DRUG INHIBITION; DRUG MECHANISM; DYSLIPIDEMIA; GENE THERAPY; HEALTH CARE COST; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; LIPID OXIDATION; LIPOPROTEIN METABOLISM; NUTRITIONAL PARAMETERS; REVIEW; RISK MANAGEMENT; TREATMENT OUTCOME; VACCINATION;

EID: 0033905320     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200060010-00005     Document Type: Review

References (294)

1. Cholesterol in the prediction of atherosclerotic disease: New perspective based on the Framingham Heart Study
2. Dyslipidemia and other risk factors for coronary artery disease
3. Hyperlipidemia
4. Lipoprotein metabolism: An overview
5. A receptor-mediated pathway for cholesterol hemostasis
6. Glycation and oxidation: A role in the pathogenesis of atherosclerosis
7. Atherosclerosis: An inflammatory disease
8. The role of lipid-lowering therapy in multiple risk factor management
9. Inflammation, the endothelium, and the acute coronary syndromes
10. Cholesterol, cholesterol lowering, and endothelial function
11. Inflammatory mechanisms of atheroma formation: Influence of fluid mechanics and lipid-derived inflammatory mediators
12. Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary artery disease
13. The new pathophysiology of coronary artery disease
14. Bacterial infections and atherosclerosis
15. State-of-the-art update and review: Clinical trials of lipid-lowering agents
16. The unstable atheromatous plaque
17. Prospects for drug therapy for hyperlipoproteinemia
18. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II)
19. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)
20. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
21. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
22. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol
23. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S)
24. Diagnosis and management of new cardiovascular risk factors
25. Primary prevention of coronary heart disease: Guidance from Framingham: A statement for health care professionals from the AHA Task Force on Risk Reduction
26. Lipoprotein(a) as a risk factor for coronary artery disease
27. Triglycerides are more important in atherosclerosis than epidemiology has suggested
28. Triglycerides as a risk factor for coronary artery disease
29. The emergence of triglycerides as a significant independent risk factor in coronary artery disease
30. Treatment of severe hypertriglyceridemia lowers plasma viscosity
31. New targets for lipid lowering and atherosclerosis prevention
32. Role of high density lipoproteins in the regression of atherosclerosis
33. Implications for the present and direction for the future
34. Homocysteine and atherosclerosis
35. Gemfibrozil decreases autoantibodies against oxidized low-density lipoprotein in men with combined hyperlipidemia
36. Gemfibrozil enhances platelet activity in patients with combined hyperlipoproteinemia
37. Direct effects of gemfibrozil on the fibrinolytic system: Diminution of synthesis of plasminogen activator inhibitor type 1
38. The decrease of plasminogen activator inhibitor after normalization of triglycerides during treatment with fibrates
39. Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of literature
40. Fenofibrate improves postprandial chylomicron clearance in II B hyperlipoproteinemia
41. Effective therapeutic measures for reducing lipoprotein (a) in patients with dyslipidemia: Lipoprotein (a) reduction with sustained-release bezafibrate
42. Reduction of Lp(a) plasma levels by bezafibrate
43. Comparison of lovastatin and bezafibrate on lipoprotein(a) plasma levels in cardiac transplant recipients
44. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb
45. Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipoproteinemia
46. Fenofibrate plus simvastatin therapy versus simvastatin plus cholestyramine therapy for familial hypercholesterolaemia
47. Efficacy and safety of a new hydroxymethylglutaryl-coenzyme a reductase inhibitor, atorvastatin, in patients with combined hyperlupidemia: Comparison with fenofibrate
48. Comparison of the efficacy and safety of fenofibrate and lovastatin in patients with primary type IIa or IIb hyperlipidemia
49. Insulin action and glucose metabolism are improved by gemfibrozil treatment in hypertriglyceridemic patients
50. Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors and incidence of coronary heart disease
51. Progression and regression of minor arterial narrowing by quantitative angiography after fenofibrate therapy
52. Effects of fenofibrate on angiographically examined coronary atherosclerosis and left ventricular function in hypercholesterolemic patients
53. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients
54. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol
55. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the bezafibrate infarction prevention trial)
56. Gemfibrozil for the secondary prevention of heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group
57. The diabetes atherosclerosis intervention study (DAIS): A study conducted in cooperation with the World Health Organization
58. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease
59. Micronised fenofibrate: A review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidemia
60. A co-operative trial in the primary prevention of ischemic heart disease using clofibrate: Report from the Committee of Principal Investigators
61. WHO cooperative trial on primary prevention of ischemic heart disease with clofibrate to lower serum cholesterol: Mortality follow-up
62. Mechanistic studies of high-density lipoproteins
63. Effect of niacin supplementation on fibrinogen levels in patients with peripheral vascular disease
64. A comparison of the efficacy and toxic effects of sustained vs. immediate-release niacin in hypercholesterolemic patients
65. Efficacy and safety of an extended-release niacin (niaspan): A long-term study
66. Clinical trial experience with extended-release niacin (niaspan): Dose-escalation study
67. A new extended-release niacin (niaspan): Efficacy, tolerability, and safety in hypercholesterolemic patients
68. Equivalent efficacy of a time-release form of niacin (niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia
69. Combination of low-dose niacin and pravastatin improves the lipid profile in diabetic patients without compromising glycemic control
70. ASHP therapeutic position statement on the safe use of niacin in the management of dyslipidemias
71. Effect of niacin on atherosclerotic cardiovascular disease
72. Clofibrate and niacin in coronary heart disease
73. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid
74. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts
75. Beneficial effects of colestipol-niacin on coronary atherosclerosis: A 4-year follow-up
76. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B
77. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens
78. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolemic patients
79. Treatment of homozygous familial hypercholesterolemia with probucol
80. Effects of probucol on xanthomata regression in familial hypercholesterolemia
81. The effects of probucol on femoral atherosclerosis: The Probucol Quantitative Regression Swedish Trial (PQRST)
82. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: Evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit
83. Probucol therapy in the prevention of restenosis after successful percutaneous transluminal coronary angioplasty
84. Probucol-associated tachyarrythmic events and QT prolongation: Importance of gender
85. Current perspectives on statins
86. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
87. Treating patients with documented atherosclerosis of National Cholesterol Education Program recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin, and simvastatin
88. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass graft
89. Results of the atorvastatin versus revascularization treatment (AVERT) study: 18 month study of aggressive lipid-lowering in patients with coronary artery disease indicated for catherization based revascularization (CR)
90. Statin trials and goals of cholesterol-lowering therapy
91. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia
92. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease
93. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease
94. HMG-CoA reductase inhibitors: In vivo effects on carotid intimal thickening in normocholesterolemic rabbits
95. Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors
96. Inhibition of cultured vascular smooth muscle cells migration by simvastatin (MK-733)
97. Antithrombotic properties of statins: Implications for cardiovascular event reduction
98. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis
99. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: The Regression Growth Evaluation Statin Study (REGRESS)
100. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I): Reduction in atherosclerosis progression and clinical events
101. Effects of simvastatin on coronary atheroma: The Multicentre Anti-Atheroma Study (MAAS)
102. Effects of monotherapy with an HMG-CoA reductase inhibition on the progression of coronary atherosclerosis as assessed by serial quantitative atherography: The Canadian Coronary Atherosclerosis Intervention trial
103. The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in the incidence of coronary heart disease
104. Hypoalphalipoproteinemia: From a mutation to drug development
105. The hypocholesterolemic effect of an antacid containing aluminum hydroxide
106. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial
107. Cholesterol-lowering effects of dietary fiber: A meta-analysis
108. Increased mRNA for low density lipoprotein receptor in livers of rabbits treated with 17 alpha-ethinyl estradiol
109. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women
110. Menopausal estrogen use, high density lipoprotein cholesterol subfraction and liver function
111. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins
112. Hormonal regulation of lipoprotein(a) levels: Effects of estrogen replacement therapy on lipoprotein(a) and acute phase reactants in postmenopausal women
113. Estrogen and coronary artery disease
114. Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women
115. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/Progestin Replacement Study (HERS) research group
116. Women with heart disease cautioned about HRT
117. Design of the Women's health initiative clinical trial and observational study: The Women's Health Initiative Study Group
118. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomized trial: The Scottish Cancer Trials Breast Group
119. Effects of raloifene on serum lipids and coagulation factors in healthy postmenopausal women
120. Clinical pharmacology of the hypocholesterolemic agent K 12.148 (lifibrol) in healthy volunteers
121. Safety and efficacy of lifibrol upon four-week administration to patients with primary hypercholesterolemia
122. Lifibrol: A novel lipid-lowering drug for therapy of hypercholesterolemia
123. Interaction of bile acids and cholesterol with nonsystemic agents having hypocholesterolemic properties
124. Colesevelam hydrochloride (cholestagel): A new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects
125. Dietary chitosan inhibits hypercholesterolaemia and atherogenesis in the apolipoprotein E-deficient mouse model of atherosclerosis
126. Comparison of synthetic saponin cholesterol absorption inhibitors in rabbits: Evidence for a non-stoichiometric, intestinal mechanism of action
127. Inhibiting cholesterol absorption with CP-88,818 (beta-tigogenin cellobioside; tiqueside): Studies in normal and hyperlipidemic subjects
128. The potential role of soluble fiber in the treatment of hypercholesterolemia
129. Inhibition of ilieal Na+/bile acid contransporter by S-8921 reduces serum cholesterol and prevents atherosclerosis in rabbits
130. Hypolipidemic activity of HOE-402 is mediated by stimulation of the LDL receptor pathway
131. Cholesterol lowering action of HOE 402 in the normolipidemic and hypercholesterolemic Golden Syrian hamster
132. ACAT inhibition decreases LDL cholesterol in rabbits fed a cholesterol-free diet: Marked changes in LDL cholesterol without changes in LDL receptor mRNA abundance
133. Inhibition of acyl CoA: Cholesterol acyltransferase decrease apolipoprotein B-100-containing lipoprotein secretion from HepG2 cells
134. Correction of dyslipoproteinemia of casein-fed rabbit by FCE 27677, a potent novel ACAT inhibitor
135. The ACAT inhibitor CI-1011 decreases ApoB100 secretion from hepG2 cells: An effect associated with enhanced intracellular degradation of ApoB
136. Effect of the ACAT inhibition, HL-004, on cholesterol metabolism in macrophage
137. The ACAT inhibitor HL-004 inhibits cholesterol absorption and lowers serum cholesterol in rats
138. Effects of the acyl-CoA: Cholesterol acyltransferase inhibitor DUP128 on cholesterol absorption-and serum cholesterol in humans
139. Effects of the ACAT inhibitor CL277,082 on cholesterol metabolism in humans
140. Comparison of CI-976, and ACAT inhibitor, and selected lipid-lowering agents for antiatherosclerotic activity in iliac-femoral and thoracic aortic lesions
141. Effect of the acyl-CoA: Cholesterol acyltransferase inhibitor E5324, on experimental atherosclerosis in rabbits
142. Effect of a novel ACAT inhibitor, E5324, on serum lipids and lipoproteins in healthy volunteers
143. Inhibitors of acyl-CoA: Cholesterol O-acyltransferase: 2. Identification and structure activity relationships of a novel series of N-alkyl-N-(heteroalkyl-substituted benzyl)-N-arylureas
144. The ACAT inhibitor, CI-1011 is effective in the prevention and regression of aortic fatty speak area in hamsters
145. Relationship between bioavailability and hypercholesterolemic activity of YM17E, an inhibitor of ACAT, in cholesterol-fed rabbits
146. HL-004, the ACAT inhibitor, prevents the progression of atherosclerosis in cholesterol-fed rabbits
147. Effects of the cholesterol absorption inhibitor SCH 48461 in combination with the HMG-CoA reductase inhibitor lovastatin in rabbits, dogs, and rhesus monkeys
148. ACA-147: An inhibitor of ACAT and of the oxidative modification of LDL
149. Inhibitory effect of a new ureidophenol derivative T-2591 on LDL oxidation and ACAT activity
150. HMG-CoA reductase and ACAT inhibitors act synergistically to lower plasma cholesterol and limit atherosclerotic lesion development in the cholesterol-fed rabbits
151. Structure-activity relationships of a series of oxysulfonyl carbamate inhibitors of acylCoA: Cholesterol O-acyltransferase (ACAT): Identification of PD 138142-15, a water soluble ACAT inhibitor displays excellent lipid regulation in rats
152. Reverse cholesterol transport: Physiology and pharmacology
153. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation
154. Effects of blocking plasma lipid transfer protein activity in the rabbit
155. Large and cholesteryl ester-rich high-density lipoprotein in cholesteryl ester transfer protein (CETP) deficiency can not protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins
156. Decreased affinity of low density lipoprotein (LDL) particles for LDL receptors in patents with cholesteryl ester transfer protein deficiency
157. Mechanisms of high-density lipoprotein reduction after probucol treatment: Changes in plasma cholesterol esterification/transfer and lipase activities
158. Inhibition of cholesterol ester transfer protein CGS 25159 and changes in lipoproteins in hamsters
159. Suppression of lipid transfer inhibition protein activity by oleate: A novel mechanism of cholesterol ester transfer protein regulation by plasma free fatty acids
160. Pravastatin modulates cholesteryl ester from HDL to apoB-containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia
161. A peptide from hog plasma that inhibits human cholesteryl ester transfer protein
162. Lipid-lowering effects of WAY-121,898, an inhibitor of pancreatic cholesteryl ester hydrolase
163. Lipoprotein lipase increases low density lipoprotein retention by subendothelial cell matrix
164. Influences of lipid-modifying agents on hemostasis
165. The novel compound NO-1886 increases lipoprotein lipase activity with resulting elevation of high-density lipoprotein cholesterol, and long-term administration inhibits atherogenesis in the coronary arteries of rats with experimental atherosclerosis
166. Antiatherogenic effects of a novel lipoprotein lipase-enhancing agent in cholesterol-fed New Zealand white rabbits
167. Overview of current issues in management of dyslipidemia
168. Zaragozic acids: A family of fungal metabolites that are picomolar competitive inhibitors of squalene synthetase
169. Massive production of farnesol-derived dicarboxylic acids in mice treated with the squalene synthetase inhibitor zaragozic acid A
170. Squalenestatin 1, a potent inhibitor of squalene synthetase, which lowers serum cholesterol in vivo
171. RPR 107393, a potent squalene synthetase inhibitor and orally effective cholesterol-lowering agent: Comparison with inhibitors of HMG-CoA reductase
172. Effects of a novel squalene epoxidase inhibitor, NB-598, on the regulation of cholesterol metabolism in Hep G2 cells
173. Inhibition of cholesterol biosynthesis by squalene epoxidase inhibitor avoids apoptotic cell death in L6 myoblasts
174. Lipid-regulating and antiatherosclerotic therapy: Current options and future approaches
175. Dyslipidemia and atherosclerosis: A forecast of pharmaceutical approaches
176. The prenylation of proteins
177. Compensatory responses to inhihition of hepatic squalene synthetase
178. Modification of experimental and clinical atherosclerosis by dietary fish oil
179. A specific 15-lipoxygenase inhibitor limits the progression and monocyte-macrophage enrichment of hypercholesterolemia-induced atherosclerosis in the rabbit
180. Interleukin 1 stimulates cholesterol esterification and cholesterol deposition in J774 monocytes-macrophages
181. The coronary drug project: Findings leading to future modifications of its protocol with respect to dextrothyroxine
182. Demonstration of potent lipid-lowering activity by a thyromimetic agent devoid of cardiovascular and thermogenic effects
183. CGS 26214, the thyroxine connection revisited
184. Lipoprotein(a) and apolipoprotein B plasma concentrations in hypothyroid, euthyroid, and hyperthyroid subjects
185. Effect of thyroid function on concentrations of lipoprotein(a)
186. Beneficial effects of a novel thyromimetic on lipoprotein metabolism
187. Anti-atherogenic effects of cholesterol vaccination
188. Vaccination against cholesterol immunologic modulation of diet-induced hypercholesterolemia and atherosclerosis
189. Army targets a potential vaccine against cholesterol
190. Immunization with homologous oxidized low density lipoprotein reduces neointimal formation after balloon injury in hypercholesterolemia rabbits
191. Gene therapy for atherosclerosis
192. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolemia
193. In vivo correction of low density lipoprotein receptor dificiency in the Watanabe heritable hyperlipidemic rabbits with recombinant adenoviruses
194. Percutaneous arterial gene transfer in a rabbit model
195. Arterial gene transfer to rabbit endothelial and smooth muscle cells using percutaneous delivery of an adenoviral vector
196. Vascular gene transfer for the treatment of restenosis and atherosclerosis
197. Gene therapy and cardiovascular disease
198. Adenovirus-mediated expression of the secreted form of basic fibroblast growth factor (FGF-2) induces cellular proliferation and angiogenesis in vivo
199. Substantial inhibition of neo-intimal response to balloon injury in the rat carotid artery using a combination of antibodies to platelet-derived growth factor-BB and basic fibroblast growth factor
200. Adenovirus-mediated gene transfer of human lipoprotein lipase ameliorates the hyperlipidemia associated with apolipoprotein E and LDL receptor deficiencies in mice
201. Overexpression of apolipoprotein E in transgenic mice: Marked reduction in plasma lipoproteins except high density lipoprotein and resistance against diet-induced hypercholesterolemia
202. Correction of hypertriglyceridemia and impaired fat tolerance in lipoprotein lipase-deficient mice by adenovirus-mediated expression of human lipoprotein lipase
203. Antisene c-myb oligonucleotide inhibit intimal arterial smooth muscle cell accumulation in vivo
204. Suppression of neointimal smooth muscle cell accumulation in vivo by antisene CDC2 and CDK2 oligonucleotides in rats carotid artery
205. Therapeutic angiogenesis: Protein and gene therapeutic delivery strategies
206. Nitric oxide synthase gene therapy rapidly reduces adhesion molecule expression and inflammatory cell infiltration in carotid arteries of cholesterol-fed rabbit
207. Chylomicron-chylomicron remnant clearance by liver and bone marrow in rabbits: Factors that modify tissue-specific uptake
208. Increased clearance of plasma cholesterol after injection of apolipoprotein E into Watanabe heritable hypercholesterolemic rabbits
209. Intravenous infusion of apolipoprotein E accelerates clearance of plasma lipoproteins in rabbits
210. Apolipoproteins E prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemia rabbits
211. High density lipoprotein plasma fractions inhibit aortic streaks in cholesterol-fed rabbits
212. 2 half-life regulates by high density lipoprotein is decreased in acute myocardial infarction and unstable angina pectoris
213. Activation of fibrinogen by apolipoproteins of high density lipoproteins in men
214. Does a HDL injection reduce the development of serum hyperlipidemia and progression of fatty streaks in cholesterol fed rabbits
215. Apolipoprotein A-I inhibits atherosclerotic lesions progression
216. Apolipoprotein A-IMilano: Accelerated binding and dissociation from lipids from a human apolipoprotein variant
217. Microsomal enzyme inducers raise plasma high-density lipoprotein cholesterol levels in healthy controls but not in patients with primary hypoalphalipoproteinemia
218. Recombinant apolipoprotein A-IMilano reduces initimal thickening after balloon injury in hypercholesterolemic rabbits
219. Rapid development of atherosclerosis lesions in the rabbit carotid artery induced by perivascular manipulation
220. Recombinant apolipoprotein A-IMilano dimer inhibits carotid intimal thickening induced by perivascular manipulation in rabbits
221. Human leukemia inhibitory factor inhibits development of experimental atherosclerosis
222. Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid
223. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids
224. Oxidation-specific epitopes in human coronary atherosclerosis are not limited to oxidized low-density lipoprotein
225. The antioxidant vitamins and cardiovascular disease: A critical review of epidemiologic and clinical trial data
226. Antiatherosclerotic effect of probucol in WHHL rabbits: Are there plasma parameters to evaluate this effect?
227. Effect of supplementation with vitamin E on LDL oxidizability and prevention of atherosclerosis
228. Extent of antioxidant protection of plasma LDL is not a predictor of the antiatherogenic effect of antioxidants
229. MDL 29311: Antioxidant with marked lipid- and glucose-lowering activity in diabetic rats and mice
230. The effects of dietary fat, antioxidants, and pro-oxidants on blood lipids, lipoproteins, and atherosclerosis
231. Natural antioxidants for the prevention of atherosclerosis
232. Modification of CHD risk by vitamin E and flax seed supplementation
233. Effects of vitamin C and E on susceptibility of plasma lipoproteins to peroxidation induced by acute smoking
234. Effect of vitamin E, Vitamin C and beta-carotene on LDL oxidation and atherosclerosis
235. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers
236. Effect of combined supplementation with α-tocopherol, ascorbate, and beta-carotene on low-density lipoprotein oxidation
237. Antioxidant nutrient supplementation reduces the susceptibility of low density lipoprotein to oxidation in patients with coronary artery disease
238. Lipoprotein oxidation, antioxidants and cardiovascular risk: Epidemiologic evidence
239. Vitamin E combined with selenium inhibits atherosclerosis in hypercholesterolemic rabbits independently of effects on plasma cholesterol concentrations
240. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking
241. Activities of silymarin and its flavonolignans upon low density lipoprotein oxidizability in vitro
242. N-acetyl-cysteine decreases the matrix-degrading capacity of macrophage-derived from cells: New target for antioxidant therapy
243. Interactions of platelets, macrophage, and lipoproteins in hypercholesterolemia: Antiatherogenic effects of HMG-CoA reductase inhibitor therapy
244. Folate and coronary heart disease
245. Cost-effectiveness of vitamin E therapy in the treatment of patients with angiographically proven coronary narrowing (CHAOS trial): Cambridge Heart Antioxidant Study
246. Effect of a Mediterranean type of diet on the rate of cardiac complications in patients with coronary artery disease: Insights into the cardioprotective effects of certain nutrients
247. A secondary prevention trial of antioxidant vitamin and cardiovascular disease in women: Rational, design, and methods. The WACS research group
248. Antiatherosclerotic and anti-oxidative effects of captopril in apolipoprotein E-deficient mice
249. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction
250. Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages
251. Peroxisome proliferator-activated receptor agonists
252. Macrophages in human atheroma contain PPAR-γ: Differentiation-dependent peroxisomal proliferator-activated receptor-γ (PPAR-γ) expression and reduction of MMP-9 activity through PPAR-γactivation in mononuclear phagocytes in vitro
253. Another potential use of troglitazone in noninsulin-dependent diabetes mellitus
254. Mode of action of peroxisome peroliferators as hypolipidemic drugs: Suppression of apolipoprotein C-III
255. Anti-atheromatous effects of fenofibrate, a hypolipidemic drug: I: Anti-atheromatous effects are independent of its hypolipidemic effect in cholesterol-fed rabbits
256. Activation of human aortic smooth-muscle cells is inhibited by PPAR-α but not by PPAR-γactivators
257. Atherosclerotic plaque caps are locally weakened when macrophage density is increased
258. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques
259. Increased secretion of tissue inhibitors of metalloproteinases 1 and 2 from the aortas of cholesterol fed rabbits partially counterbalances increased metalloproteinase activity
260. Increased secretion of gelatinases A and B from the aortas of cholesterol fed rabbits: Relationship to lesion severity
261. Microscopic localization of active proteases by in situ zymography: Detection of matrix metalloproteinase activity in vascular tissue
262. Metalloproteinase inhibitors and the prevention of connective tissue breakdown
263. Adenovirus mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointima formation in human saphenous vein
264. Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology
265. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels
266. A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism
267. Targeted mutation reveals a central role for SR-BI in hepatic selective uptake of high density lipoprotein cholesterol
268. Apolipoproteins of HDL can directly mediate binding to the scavenger receptor SR-BI, an HDL receptor that mediates selective lipid uptake
269. Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux
270. Scavenger receptor, class B, type I-dependent stimulation of cholesterol esterification by high density lipoproteins, low lipoproteins, and nonlipoprotein cholesterol
271. Decreased atherosclerosis in heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor BI transgene
272. Probucol enhances selective uptake of HDL-associated cholesteryl esters in vitro by a scavenger receptor B-I-dependent mechanism
273. Polyunsaturated fatty acids up-regulate hepatic scavenger receptor B1 (SR-BI) expression and HDL cholesteryl ester uptake in the hamster
274. Paroxonase genotypes lipoprotein lipase activity, and HDL
275. Dietary fats and coronary heart disease
276. Effects of dietary stearic acid on plasma cholesterol and lipoprotein levels
277. Low density lipoprotein rich in oleic acid is protected against oxidative modification: Implication for dietary prevention of atherosclerosis
278. Direct vascular atherogenic effects of oleic acid: A clue to the cardioprotective effects of the Mediterranean diet
279. Marine oil capsule therapy for the treatment of hyperlipidemia
280. Fish consumption and the 30-year risk of fatal myocardial infarction
281. Omega-3 ethyl ester concentration decrease total apolipoproteins CIII and increase antithrombin III in postmyocardial infarction patients
282. Effects of fish oil in lipid peroxidation and antioxidant defense system of plasma and lipoprotein fraction in rats
283. The hypocholesterolemic effects of beta-glucan in oatmeal and oatbran: A dose-controlled study
284. Cholesterol-lowering effects of psyllium hydrophilic mucilloid
285. The regulatory status of medical food and dietary supplements in the United States
286. Dietary L-arginine decreases myoinitimal cell proliferation and vascular monocyte accumulation in cholesterol-fed rabbits
287. Coronary vascular nitric oxide activity in hypertension and hypercholesterolemia
288. Effects of L-arginine supplementation on endothelium-dependent coronary vasodilation in patients with angina pectoris and normal coronary arteries
289. New guidelines for managing hypercholesterolemia
290. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)
291. Clinical experience and future directions for low-density lipoprotein apheresis in the United States